These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

221 related items for PubMed ID: 18091519

  • 1. A lower incidence of cytomegalovirus infection in de novo heart transplant recipients randomized to everolimus.
    Hill JA, Hummel M, Starling RC, Kobashigawa JA, Perrone SV, Arizón JM, Simonsen S, Abeywickrama KH, Bara C.
    Transplantation; 2007 Dec 15; 84(11):1436-42. PubMed ID: 18091519
    [Abstract] [Full Text] [Related]

  • 2. Everolimus is associated with a reduced incidence of cytomegalovirus infection following de novo cardiac transplantation.
    Kobashigawa J, Ross H, Bara C, Delgado JF, Dengler T, Lehmkuhl HB, Wang SS, Dong G, Witte S, Junge G, Potena L.
    Transpl Infect Dis; 2013 Apr 15; 15(2):150-62. PubMed ID: 23013440
    [Abstract] [Full Text] [Related]

  • 3. Lower incidence of cytomegalovirus infection with everolimus versus mycophenolate mofetil in de novo cardiac transplant recipients: a randomized, multicenter study.
    Viganò M, Dengler T, Mattei MF, Poncelet A, Vanhaecke J, Vermes E, Kleinloog R, Li Y, Gezahegen Y, Delgado JF, RAD A2411 Study Investigators.
    Transpl Infect Dis; 2010 Feb 15; 12(1):23-30. PubMed ID: 19744284
    [Abstract] [Full Text] [Related]

  • 4. From clinical trials to clinical practice: an overview of Certican (everolimus) in heart transplantation.
    Valantine H, Zuckermann A.
    J Heart Lung Transplant; 2005 Apr 15; 24(4 Suppl):S185-90; discussion S210-1. PubMed ID: 15774320
    [Abstract] [Full Text] [Related]

  • 5. Reduced risk of cytomegalovirus infection in solid organ transplant recipients treated with sirolimus: a pooled analysis of clinical trials.
    Demopoulos L, Polinsky M, Steele G, Mines D, Blum M, Caulfield M, Adamkovic A, Liu Q, Harler MB, Hahn C, Singh A.
    Transplant Proc; 2008 Jun 15; 40(5):1407-10. PubMed ID: 18589118
    [Abstract] [Full Text] [Related]

  • 6. Prevention of acute rejection and allograft vasculopathy by everolimus in cardiac transplants recipients: a 24-month analysis.
    Viganò M, Tuzcu M, Benza R, Boissonnat P, Haverich A, Hill J, Laufer G, Love R, Parameshwar J, Pulpón LA, Renlund D, Abeywickrama K, Cretin N, Starling RC, Eisen HJ, RAD B253 Study Group.
    J Heart Lung Transplant; 2007 Jun 15; 26(6):584-92. PubMed ID: 17543781
    [Abstract] [Full Text] [Related]

  • 7. Review of cytomegalovirus infection findings with mammalian target of rapamycin inhibitor-based immunosuppressive therapy in de novo renal transplant recipients.
    Nashan B, Gaston R, Emery V, Säemann MD, Mueller NJ, Couzi L, Dantal J, Shihab F, Mulgaonkar S, Seun Kim Y, Brennan DC.
    Transplantation; 2012 Jun 15; 93(11):1075-85. PubMed ID: 22683823
    [Abstract] [Full Text] [Related]

  • 8. Role of immunosuppressive regimen on the incidence and characteristics of cytomegalovirus infection in heart transplantation: a single-center experience with preemptive therapy.
    De Santo LS, Romano G, Mastroianni C, Roberta C, Della Corte A, Amarelli C, Maiello C, Giannolo B, Marra C, Ragone E, Grimaldi M, Utili R, Scardone M, Cotrufo M.
    Transplant Proc; 2005 Jun 15; 37(6):2684-7. PubMed ID: 16182784
    [Abstract] [Full Text] [Related]

  • 9. Acute rejection and cardiac allograft vascular disease is reduced by suppression of subclinical cytomegalovirus infection.
    Potena L, Holweg CT, Chin C, Luikart H, Weisshaar D, Narasimhan B, Fearon WF, Lewis DB, Cooke JP, Mocarski ES, Valantine HA.
    Transplantation; 2006 Aug 15; 82(3):398-405. PubMed ID: 16906040
    [Abstract] [Full Text] [Related]

  • 10. Recommendations for use of everolimus after heart transplantation: results from a Latin-American Consensus Meeting.
    Bocchi EA, Ahualli L, Amuchastegui M, Boullon F, Cerutti B, Colque R, Fernandez D, Fiorelli A, Olaya P, Vulcado N, Perrone SV.
    Transplant Proc; 2006 Apr 15; 38(3):937-42. PubMed ID: 16647515
    [Abstract] [Full Text] [Related]

  • 11. Does cytomegalovirus serology impact outcome after pediatric heart transplantation?
    Mahle WT, Fourshee MT, Naftel DM, Alejos JC, Caldwell RL, Uzark K, Berg A, Kanter KR, Pediatric Heart Transplant Study Group.
    J Heart Lung Transplant; 2009 Dec 15; 28(12):1299-305. PubMed ID: 19783178
    [Abstract] [Full Text] [Related]

  • 12. 24-week oral ganciclovir prophylaxis in kidney recipients is associated with reduced symptomatic cytomegalovirus disease compared to a 12-week course.
    Doyle AM, Warburton KM, Goral S, Blumberg E, Grossman RA, Bloom RD.
    Transplantation; 2006 Apr 27; 81(8):1106-11. PubMed ID: 16641594
    [Abstract] [Full Text] [Related]

  • 13. Cytomegalovirus infection in renal transplant recipients.
    Carstens J, Andersen HK, Spencer E, Madsen M.
    Transpl Infect Dis; 2006 Dec 27; 8(4):203-12. PubMed ID: 17116133
    [Abstract] [Full Text] [Related]

  • 14. Who among cytomegalovirus-seropositive liver transplant recipients is at risk for cytomegalovirus infection?
    Singh N, Wannstedt C, Keyes L, Wagener MM, Cacciarelli TV.
    Liver Transpl; 2005 Jun 27; 11(6):700-4. PubMed ID: 15915496
    [Abstract] [Full Text] [Related]

  • 15. Influence of everolimus on cyclosporine Neoral pharmacokinetics in Chinese de novo cardiac transplant recipients.
    Wang CH, Chou NK, Wu FL, Ko WJ, Tsao CI, Chi NH, Hsu RB, Wang SS.
    Transplant Proc; 2006 Sep 27; 38(7):2032-4. PubMed ID: 16979990
    [Abstract] [Full Text] [Related]

  • 16. Sirolimus exposure during the early post-transplant period reduces the risk of CMV infection relative to tacrolimus in renal allograft recipients.
    Haririan A, Morawski K, West MS, El-Amm JM, Doshi MD, Cincotta E, Alangaden GJ, Chandrasekar P, Gruber SA.
    Clin Transplant; 2007 Sep 27; 21(4):466-71. PubMed ID: 17645705
    [Abstract] [Full Text] [Related]

  • 17. Combined CMV prophylaxis improves outcome and reduces the risk for bronchiolitis obliterans syndrome (BOS) after lung transplantation.
    Ruttmann E, Geltner C, Bucher B, Ulmer H, Höfer D, Hangler HB, Semsroth S, Margreiter R, Laufer G, Müller LC.
    Transplantation; 2006 May 27; 81(10):1415-20. PubMed ID: 16732179
    [Abstract] [Full Text] [Related]

  • 18. HLA-DQ3 is a probable risk factor for CMV infection in high-risk kidney transplant patients.
    Varga M, Rajczy K, Telkes G, Hídvégi M, Péter A, Remport A, Korbonits M, Fazakas J, Toronyi E, Sárváry E, Kóbori L, Járay J.
    Nephrol Dial Transplant; 2008 Aug 27; 23(8):2673-8. PubMed ID: 18332066
    [Abstract] [Full Text] [Related]

  • 19. Immune monitoring of anti cytomegalovirus antibodies and risk of cytomegalovirus disease in heart transplantation.
    Sarmiento E, Lanio N, Gallego A, Rodriguez-Molina J, Navarro J, Fernandez-Yañez J, Palomo J, Rodríguez-Hernández C, Ruiz M, Alonso R, Fernandez-Cruz E, Carbone J.
    Int Immunopharmacol; 2009 Jun 27; 9(6):649-52. PubMed ID: 18940269
    [Abstract] [Full Text] [Related]

  • 20. [Importance of screening for antibodies to cytomegalovirus in organ transplantation].
    Milbradt H, Flik J, Stangel W, Heigel R.
    Beitr Infusionsther; 1990 Jun 27; 26():33-6. PubMed ID: 1703866
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.